Insider · CIK 0002059193
Lavina Talukdar
Files at MNPR (Monopar Therapeutics). First filing -, latest -.
Lavina Talukdar files SEC Form 4 as director at MNPR (Monopar Therapeutics). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Lavina Talukdar has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 1 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Dec 2, 2025 | MNPR Monopar Therapeutics | AGrant or award Stock Optionsderivative | +2,924 | $0.00 | $0 | 2,924 | Dec 8, 2025 |
Questions about Lavina Talukdar
Answered from the filings on this page, as of the latest one.
Is Lavina Talukdar buying or selling?
Lavina Talukdar has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Lavina Talukdar's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Lavina Talukdar has 0.
Where does Lavina Talukdar file Form 4?
Lavina Talukdar has filed Form 4 at MNPR (Monopar Therapeutics). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.